BETHESDA, Md. — August 12, 2025 — Leads & Copy — Gain Therapeutics, Inc. (Nasdaq: GANX) reported financial results for the quarter ended June 30, 2025, and provided a corporate update. The company completed target enrollment for its Phase 1b study evaluating lead candidate GT-02287 in Parkinson’s disease with or without a GBA1 mutation, earlier than anticipated.
As of June 30, 2025, 16 patients were enrolled in the Phase 1b study. Gain expects the analysis of participants’ functional changes and biomarker activity from cerebrospinal fluid at 90 days to be available during 4Q 2025. The company recently submitted a request to extend the dosing duration of the Phase 1b study beyond the current 90 days allowable in the original protocol; an update is expected in the coming weeks.
In July 2025, Gain completed an underwritten public offering that resulted in approximately $7.1 million of net proceeds.
According to Gene Mack, President and CEO of Gain, the company looks forward to reporting the analysis of both functional changes and biomarker activity during 4Q 2025, which will help in planning the design of the Phase 2 clinical trial for GT-02287.
Contact: Apaar Jammu, Manager, Investor Relations and Public Relations, ajammu@gaintherapeutics.com
Source: Gain Therapeutics, Inc.
